Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease

Boyang Qiu, Julie Ruston, Henk Granzier, Monica J. Justice, James J. Dowling

Research output: Contribution to journalArticle

Abstract

Nemaline myopathy is a rare neuromuscular disorder that affects 1 in 50,000 live births, with prevalence as high as 1 in 20,000 in certain populations. 13 genes have been linked to nemaline myopathy (NM), all of which are associated with the thin filament of the muscle sarcomere. Of the 13 associated genes, mutations in NEBULIN (NEB) accounts for up to 50% of all cases. Currently, the disease is incompletely understood and there are no available therapeutics for patients. To address this urgent need for effective treatments for patients affected by NM, we conducted a large scale chemical screen in a zebrafish model of NEB-related NM and an N-ethyl-N-nitrosourea (ENU)-based genetic screen in a mouse model of NEB exon 55 deletion, the most common NEB mutation in NM patients. Neither screen was able to identify a candidate for therapy development, highlighting the need to transition from conventional chemical therapeutics to gene-based therapies for the treatment of NM.

Original languageEnglish (US)
Article numberbio044867
JournalBiology Open
Volume8
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Nemaline Myopathies
modifiers (genes)
disease models
muscular diseases
Genes
Ethylnitrosourea
therapeutics
Muscle
Exons
N-ethyl-N-nitrosourea
neuromuscular disorders
mutation
Therapeutics
Sarcomeres
Mutation
sarcomeres
genes
Live Birth
Zebrafish
Danio rerio

Keywords

  • Mice
  • Modifier screen
  • NEBULIN
  • Nemaline myopathy
  • Zebrafish

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease. / Qiu, Boyang; Ruston, Julie; Granzier, Henk; Justice, Monica J.; Dowling, James J.

In: Biology Open, Vol. 8, No. 9, bio044867, 01.01.2019.

Research output: Contribution to journalArticle

Qiu, Boyang ; Ruston, Julie ; Granzier, Henk ; Justice, Monica J. ; Dowling, James J. / Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease. In: Biology Open. 2019 ; Vol. 8, No. 9.
@article{b9d2920ac84b478d9956d44ce78dd6a7,
title = "Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease",
abstract = "Nemaline myopathy is a rare neuromuscular disorder that affects 1 in 50,000 live births, with prevalence as high as 1 in 20,000 in certain populations. 13 genes have been linked to nemaline myopathy (NM), all of which are associated with the thin filament of the muscle sarcomere. Of the 13 associated genes, mutations in NEBULIN (NEB) accounts for up to 50{\%} of all cases. Currently, the disease is incompletely understood and there are no available therapeutics for patients. To address this urgent need for effective treatments for patients affected by NM, we conducted a large scale chemical screen in a zebrafish model of NEB-related NM and an N-ethyl-N-nitrosourea (ENU)-based genetic screen in a mouse model of NEB exon 55 deletion, the most common NEB mutation in NM patients. Neither screen was able to identify a candidate for therapy development, highlighting the need to transition from conventional chemical therapeutics to gene-based therapies for the treatment of NM.",
keywords = "Mice, Modifier screen, NEBULIN, Nemaline myopathy, Zebrafish",
author = "Boyang Qiu and Julie Ruston and Henk Granzier and Justice, {Monica J.} and Dowling, {James J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1242/bio.044867",
language = "English (US)",
volume = "8",
journal = "Biology Open",
issn = "2046-6390",
publisher = "Company of Biologists Ltd",
number = "9",

}

TY - JOUR

T1 - Failure to identify modifiers of NEBULIN-related nemaline myopathy in two pre-clinical models of the disease

AU - Qiu, Boyang

AU - Ruston, Julie

AU - Granzier, Henk

AU - Justice, Monica J.

AU - Dowling, James J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Nemaline myopathy is a rare neuromuscular disorder that affects 1 in 50,000 live births, with prevalence as high as 1 in 20,000 in certain populations. 13 genes have been linked to nemaline myopathy (NM), all of which are associated with the thin filament of the muscle sarcomere. Of the 13 associated genes, mutations in NEBULIN (NEB) accounts for up to 50% of all cases. Currently, the disease is incompletely understood and there are no available therapeutics for patients. To address this urgent need for effective treatments for patients affected by NM, we conducted a large scale chemical screen in a zebrafish model of NEB-related NM and an N-ethyl-N-nitrosourea (ENU)-based genetic screen in a mouse model of NEB exon 55 deletion, the most common NEB mutation in NM patients. Neither screen was able to identify a candidate for therapy development, highlighting the need to transition from conventional chemical therapeutics to gene-based therapies for the treatment of NM.

AB - Nemaline myopathy is a rare neuromuscular disorder that affects 1 in 50,000 live births, with prevalence as high as 1 in 20,000 in certain populations. 13 genes have been linked to nemaline myopathy (NM), all of which are associated with the thin filament of the muscle sarcomere. Of the 13 associated genes, mutations in NEBULIN (NEB) accounts for up to 50% of all cases. Currently, the disease is incompletely understood and there are no available therapeutics for patients. To address this urgent need for effective treatments for patients affected by NM, we conducted a large scale chemical screen in a zebrafish model of NEB-related NM and an N-ethyl-N-nitrosourea (ENU)-based genetic screen in a mouse model of NEB exon 55 deletion, the most common NEB mutation in NM patients. Neither screen was able to identify a candidate for therapy development, highlighting the need to transition from conventional chemical therapeutics to gene-based therapies for the treatment of NM.

KW - Mice

KW - Modifier screen

KW - NEBULIN

KW - Nemaline myopathy

KW - Zebrafish

UR - http://www.scopus.com/inward/record.url?scp=85072959201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072959201&partnerID=8YFLogxK

U2 - 10.1242/bio.044867

DO - 10.1242/bio.044867

M3 - Article

AN - SCOPUS:85072959201

VL - 8

JO - Biology Open

JF - Biology Open

SN - 2046-6390

IS - 9

M1 - bio044867

ER -